Fig. 1From: The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory studyProgression-free survival (a) for all the patients and (b) by Metastasis VolumeBack to article page